Alliqua, Celgene deal

Celgene's Celgene Cellular Therapeutics subsidiary granted Alliqua U.S. rights to develop and commercialize wound care products Biovance and Extracellular Matrix (ECM). Celgene will make a $6 million equity investment comprised of 1.7 million shares of Alliqua common stock at $3.59 per share. The price is a 4% premium to Alliqua's close of $3.46 on Nov. 18, the day before the deal was announced. Celgene will also receive a five-year warrant to purchase 836,237 shares at $5.69. Celgene also received a right to appoint a director to Alliqua's board and is eligible to receive milestones and royalties. ...